Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Seven new option listings and two option delistings on December 3rd » 08:30
12/03/20
12/03
08:30
12/03/20
08:30
ATRO

Astronics

$12.46 /

+0.43 (+3.57%)

, DPW

DPW Holdings

$4.50 /

-0.04 (-0.88%)

, LAZR

Luminar

$0.00 /

+ (+0.00%)

, PTPI

Petros Pharmaceuticals

$3.86 /

-0.88 (-18.57%)

, SUNW

Sunworks

$4.09 /

-0.16 (-3.76%)

, GMHI

Merged into LAZR

$18.10 /

+1.1 (+6.47%)

, NTRP

Neurotrope

$0.94 /

-0.01 (-1.05%)

New option listings for…

New option listings for December 3rd include Astronics (ATRO), Digital Power (DPW), Virtus Terranova US Quality Momentum ETF (JOET), Luminar Technologies Inc (Class A Stock) (LAZR), Petros Pharmaceuticals Inc (PTPI), RedBall Acquisition Corp (Class A Stock) (RBAC), and Sunworks (SUNW). Option delistings effective December 3rd include Gores Metropoulos Inc (Class A Stock) (GMHI) and Neurotrope Inc (NTRP).

ShowHide Related Items >><<
SUNW Sunworks
$4.09 /

-0.16 (-3.76%)

NTRP Neurotrope
$0.94 /

-0.01 (-1.05%)

LAZR Luminar
$0.00 /

+ (+0.00%)

GMHI Merged into LAZR
$18.10 /

+1.1 (+6.47%)

DPW DPW Holdings
$4.50 /

-0.04 (-0.88%)

ATRO Astronics
$12.46 /

+0.43 (+3.57%)

ATRO Astronics
$12.46 /

+0.43 (+3.57%)

12/01/20 Truist
Astronics upgraded to Hold from Sell at Truist
12/01/20 Truist
Astronics upgraded to Hold from Sell at Truist
11/20/20 CJS Securities
Astronics upgraded to Outperform from Market Perform at CJS Securities
11/20/20 Canaccord
Canaccord upgrades Astronics, more than doubles target to $15
DPW DPW Holdings
$4.50 /

-0.04 (-0.88%)

LAZR Luminar
$0.00 /

+ (+0.00%)

PTPI Petros Pharmaceuticals
$3.86 /

-0.88 (-18.57%)

SUNW Sunworks
$4.09 /

-0.16 (-3.76%)

04/02/20 Roth Capital
Sunworks downgraded to Neutral from Buy at Roth Capital
GMHI Merged into LAZR
$18.10 /

+1.1 (+6.47%)

10/14/20 Northland
Gores Metropoulos initiated with an Outperform at Northland
NTRP Neurotrope
$0.94 /

-0.01 (-1.05%)

ATRO Astronics
$12.46 /

+0.43 (+3.57%)

GMHI Merged into LAZR
$18.10 /

+1.1 (+6.47%)

DPW DPW Holdings
$4.50 /

-0.04 (-0.88%)

GMHI Merged into LAZR
$18.10 /

+1.1 (+6.47%)

Hot Stocks
Neurotrope and Metuchen Pharmaceuticals complete merger into Petros Pharma » 09:13
12/02/20
12/02
09:13
12/02/20
09:13
NTRP

Neurotrope

$0.94 /

-0.12 (-11.32%)

Neurotrope and Metuchen…

Neurotrope and Metuchen Pharmaceuticals, a privately held biopharmaceutical company focused on therapeutics for men's health conditions, announced the completion of their merger following the satisfaction of all closing conditions required by the amended merger agreement. Neurotrope shareholders also approved the spin-off of substantially all of Neurotrope's existing assets, operations and liabilities, except for certain cash retained in accordance with the terms of the Merger Agreement, into a separately traded public company. Neurotrope and Metuchen have merged in an all-stock transaction forming a newly traded holding company named Petros Pharmaceuticals. Petros' shares will commence trading on Nasdaq on December 2, under the ticker symbol "PTPI". Neurotrope shareholders will initially own approximately 49% of the combined company and Metuchen shareholders will initially own approximately 51%. Metuchen shareholders also may receive additional shares of Petros common stock issuable upon the achievement of certain milestones. Petros' lead commercial asset is Stendra, an FDA-approved erectile dysfunction treatment. Petros is currently exploring the potential to convert Stendra from prescription-only status to non-prescription status. Petros will be led by Fady Boctor, Chief Commercial Officer of Metuchen, who has been named President and CCO.

ShowHide Related Items >><<
NTRP Neurotrope
$0.94 /

-0.12 (-11.32%)

Hot Stocks
Neurotrope board approves spin-off of Neurotrope Bioscience » 09:02
11/20/20
11/20
09:02
11/20/20
09:02
NTRP

Neurotrope

$0.96 /

-0.0048 (-0.50%)

Neurotrope announced that…

Neurotrope announced that its Board of Directors has approved the conditional distribution and set the shareholder of record and distribution dates in connection with the previously announced spin-off of its wholly-owned subsidiary, Neurotrope Bioscience. Subject to the closing of Neurotrope's proposed merger with Metuchen Pharmaceuticals, shareholders and certain warrant holders of record of Neurotrope on November 30 will receive on December 7, a dividend at the rate of (i) one share of NBI common stock for every five shares of Neurotrope common stock held, (ii) one share of NBI common stock for every five shares of Neurotrope common stock issuable upon conversion of Neurotrope preferred stock held and (iii) one share of NBI common stock for every five shares of Neurotrope common stock issuable upon exercise of certain Neurotrope warrants held that are entitled to participate in the spin-off pursuant to the terms thereof. Any fractional shares will be paid in cash. Neurotrope and Metuchen previously announced their intent to merge in an all-stock transaction resulting in the formation of a holding company to be named Petros Pharmaceuticals, which expects to trade on the Nasdaq Capital Market under the symbol "PTPI" following the closing of the merger. Neurotrope's meeting of shareholders to approve the proposed merger and other matters is scheduled for November 25. Neurotrope expects that NBI common stock will be quoted on the OTCQB market of the OTC Markets Group under a symbol that is yet to be determined.

ShowHide Related Items >><<
NTRP Neurotrope
$0.96 /

-0.0048 (-0.50%)

Over a quarter ago
Hot Stocks
Neurotrope announces dosing of first patient in Phase 2 study of Bryostatin-1 » 09:02
10/06/20
10/06
09:02
10/06/20
09:02
NTRP

Neurotrope

$1.07 /

+0.01 (+0.94%)

Neurotropey announced…

Neurotropey announced dosing of the first patient in its ongoing, long-term Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease, or AD. The study will be conducted in collaboration with the National Institutes of Health, or NIH, under a $2.7M grant to Neurotrope. The new Phase 2 clinical study, which is expected to enroll approximately 100 patients, will evaluate Bryostatin-1 in the absence of Namenda(R) (memantine) for a six-month period, which will include two 11-week dosing cycles. The study will focus on AD patients with pre-specified moderately severe and moderate disease, including a patient population that demonstrated the most evidence of benefit in a prior study, and will focus on assessing sustained cognitive benefit as measured by the Severe Impairment Battery ("SIB") score, a widely accepted measure of cognitive function in advanced dementia patients. Analysis of the data will be conducted in consultation with Dr. Richard Thompson, Senior Scientist from the Bloomberg School of Public Health at Johns Hopkins University.

ShowHide Related Items >><<
NTRP Neurotrope
$1.07 /

+0.01 (+0.94%)

Hot Stocks
Neurotrope shareholders to own 49% of Petros under revised Metuchen merger » 09:21
09/30/20
09/30
09:21
09/30/20
09:21
NTRP

Neurotrope

$1.12 /

+ (+0.00%)

Neurotrope and Metuchen…

Neurotrope and Metuchen Pharmaceuticals, a privately held biopharmaceutical company focused on therapeutics for men's health conditions, have entered into an amendment to their definitive merger agreement under which the consideration due to Neurotrope stockholders will increase to 49% of the combined company on a pro forma basis and based upon the final Neurotrope common stock share count at close. Under terms of the Merger Agreement dated July 23, Neurotrope stockholders were to own approximately 22.5% of the combined company. Neurotrope and Metuchen previously announced their intent to merge in an all-stock transaction resulting to form a NASDAQ-traded holding company to be named Petros Pharmaceuticals. As part of the Amended Merger Agreement, Neurotrope shareholders currently representing 34% of the company's outstanding shares have signed a shareholder rights agreement in support of the merger. Under the Amended Merger Agreement, upon closing of the transaction, Neurotrope's current lead asset, Bryostatin-1 to treat neurodegeneration, and substantially all of its existing assets, operations and liabilities, except for cash retained by Petros in accordance with the terms of the Amended Merger Agreement, will be spun-out into a new, separately traded company. The Amended Merger Agreement has been approved by the boards of directors of both companies. Petros will focus on its two core assets: Stendra, the only oral, patented erectile disfunction product on the market, as well as H-100, a topical treatment candidate for Peyronie's disease. Petros will be led by Fady Boctor, Chief Commercial Officer of Metuchen, who will be named President and CCO. A new board of directors will be installed and John Shulman will become Executive Chairman of the Board. Charles Ryan, Neurotrope CEO, will transition to a senior consulting role to Petros. Petros will explore the potential to convert Stendra from prescription-only status to non-prescription status. Petros will partner with Foundation Consumer Healthcare in this effort. Neurotrope plans to hold a special meeting of stockholders to approve the pending transaction mid-Q4. The transaction is expected to close shortly thereafter, subject to customary closing conditions, including approval of the amended Merger Agreement by Neurotrope stockholders.

ShowHide Related Items >><<
NTRP Neurotrope
$1.12 /

+ (+0.00%)

Hot Stocks
Neurotrope signs agreement with Worldwide Clinical Trials for Alzheimer's study » 09:10
07/30/20
07/30
09:10
07/30/20
09:10
NTRP

Neurotrope

$1.12 /

-0.02 (-1.75%)

Neurotrope's…

Neurotrope's wholly-owned subsidiary Neurotrope Bioscience, or NBI, has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease. The Phase 2 clinical study is being conducted in collaboration with the National Institutes of Health under a $2.7M grant to Neurotrope. This Phase 2 clinical study is expected to enroll approximately 100 patients, will evaluate Bryostatin-1 in the absence of Namenda for a 6-month period, which will include two 11-week dosing cycles. Neurotrope expects to dose the first patient in late Q3 or early Q4. This new Phase 2 study is supported by Phase 2 clinical data from a completed pilot trial in which Bryostatin-1 was well tolerated and showed early signals of cognitive benefit, including a 5.0 improvement in SIB score compared to baseline in the Moderate Stratum cohort in the non-Namenda group.

ShowHide Related Items >><<
NTRP Neurotrope
$1.12 /

-0.02 (-1.75%)

NTRP Neurotrope
$1.12 /

-0.02 (-1.75%)

09/11/19 Janney Montgomery Scott
Neurotrope downgraded to Neutral from Buy at Janney Montgomery Scott
09/09/19 Maxim
Maxim downgrades Neurotrope to Hold amid 80% share selloff
09/09/19 Maxim
Neurotrope downgraded to Hold from Buy at Maxim
NTRP Neurotrope
$1.12 /

-0.02 (-1.75%)

Hot Stocks
Neurotrope partners with BryoLogyx for childhood leukemia trial » 08:47
06/10/20
06/10
08:47
06/10/20
08:47
NTRP

Neurotrope

$1.48 /

+0.05 (+3.50%)

Neurotrope entered into a…

Neurotrope entered into a strategic agreement with BryoLogyx for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, a global CDMO provider of drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimer's disease and other neurodegenerative diseases and for potential commercial drug supply if regulatory approval is received. BryoLogyx will supply Neurotrope with specified amounts of synthetic, GMP-grade Bryostatin-1. BryoLogyx will pay a fee on gross revenues generated by the commercial sale of Bryostatin-1 product sold by BryoLogyx for the treatment of ALL. In exchange, Neurotrope will transfer to BryoLogyx the program right to develop Bryostatin-1 with CAR-T therapy for the potential treatment of CD22+ B-cell ALL with the National Cancer Institute. Neurotrope has entered into a definitive merger agreement pursuant to which Metuchen Pharmaceuticals and Neurotrope have agreed to merge in an all-stock transaction resulting in a newly formed holding company which will be named Petros Pharmaceuticals. Upon closing of the transaction, Bryostatin-1 and substantially all of Neurotrope's existing assets, operations and liabilities, except for cash retained by Petros in accordance with the terms of the merger agreement, will be spun-out into a new, separately traded company which will retain the name Neurotrope Bioscience.

ShowHide Related Items >><<
NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

09/11/19 Janney Montgomery Scott
Neurotrope downgraded to Neutral from Buy at Janney Montgomery Scott
09/09/19 Maxim
Maxim downgrades Neurotrope to Hold amid 80% share selloff
09/09/19 Maxim
Neurotrope downgraded to Hold from Buy at Maxim
06/18/19 Janney Montgomery Scott
Neurotrope initiated with a Buy at Janney Montgomery Scott
NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

Conference/Events
Neurotrope to host business news update conference call » 10:25
05/28/20
05/28
10:25
05/28/20
10:25
NTRP

Neurotrope

$1.43 /

-0.05 (-3.38%)

Management holds a…

Management holds a business news update conference call on May 28 at 11 am. Webcast Link

ShowHide Related Items >><<
NTRP Neurotrope
$1.43 /

-0.05 (-3.38%)

NTRP Neurotrope
$1.43 /

-0.05 (-3.38%)

09/11/19 Janney Montgomery Scott
Neurotrope downgraded to Neutral from Buy at Janney Montgomery Scott
09/09/19 Maxim
Maxim downgrades Neurotrope to Hold amid 80% share selloff
09/09/19 Maxim
Neurotrope downgraded to Hold from Buy at Maxim
06/18/19 Janney Montgomery Scott
Neurotrope initiated with a Buy at Janney Montgomery Scott
NTRP Neurotrope
$1.43 /

-0.05 (-3.38%)

Hot Stocks
Neurotrope launches Bryostatin clinical trial for Alzheimer's with NIH » 09:04
05/28/20
05/28
09:04
05/28/20
09:04
NTRP

Neurotrope

$1.48 /

+0.05 (+3.50%)

Neurotrope announced the…

Neurotrope announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease. The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health under a $2.7M grant to Neurotrope. The company has engaged Worldwide Clinical Trials to initiate site recruitment and activation. Neurotrope has entered into a definitive merger agreement pursuant to which Metuchen Pharmaceuticals and Neurotrope have agreed to merge in an all-stock transaction resulting in a newly formed holding company focused on men's health conditions, which will be named Petros Pharmaceuticals. Upon closing of the transaction, Bryostatin-1 and substantially all of Neurotrope's existing assets, operations and liabilities, except for cash retained by Petros in accordance with the terms of the merger agreement, will be spun-out into a new, separately traded company which will retain the name Neurotrope Bioscience. The new Phase 2 clinical study, which is expected to enroll approximately 100 patients, will evaluate Bryostatin-1 in the absence of Namenda for a 6-month period. Neurotrope expects to dose the first patient in late Q3 or early Q4 this year.

ShowHide Related Items >><<
NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

09/11/19 Janney Montgomery Scott
Neurotrope downgraded to Neutral from Buy at Janney Montgomery Scott
09/09/19 Maxim
Maxim downgrades Neurotrope to Hold amid 80% share selloff
09/09/19 Maxim
Neurotrope downgraded to Hold from Buy at Maxim
06/18/19 Janney Montgomery Scott
Neurotrope initiated with a Buy at Janney Montgomery Scott
NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

Conference/Events
Neurotrope to host business news update conference call » 04:55
05/28/20
05/28
04:55
05/28/20
04:55
NTRP

Neurotrope

$1.48 /

+0.05 (+3.50%)

Management holds a…

Management holds a business news update conference call on May 28 at 11 am. Webcast Link

ShowHide Related Items >><<
NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

09/11/19 Janney Montgomery Scott
Neurotrope downgraded to Neutral from Buy at Janney Montgomery Scott
09/09/19 Maxim
Maxim downgrades Neurotrope to Hold amid 80% share selloff
09/09/19 Maxim
Neurotrope downgraded to Hold from Buy at Maxim
06/18/19 Janney Montgomery Scott
Neurotrope initiated with a Buy at Janney Montgomery Scott
NTRP Neurotrope
$1.48 /

+0.05 (+3.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.